Oximezin (Cefotaxime)

Cefotaxime, the active ingredient in Oximezin, is a third-generation cephalosporin antibiotic presented as a sterile powder for intravenous infusion use. It treats severe bacterial infections and is commonly administered in hospital settings.

GNH USA supplies Oximezin as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres and pharmacies worldwide.

Oximezin is a broad‑spectrum cephalosporin that targets Gram‑negative and Gram‑positive bacterial pathogens in several clinical contexts.

- Lower respiratory tract infections: helps eradicate the causative bacteria and improve pulmonary function. - Urinary tract infections: eliminates the infecting organisms and reduces symptom duration. - Intra‑abdominal infections: provides coverage against mixed aerobic and anaerobic flora, aiding recovery. - Skin and soft‑tissue infections: treats susceptible Staphylococcus and Streptococcus species. - Septicemia and bacteremia: rapidly clears bacteria from the bloodstream, supporting hemodynamic stability.

Adverse reactions to cefotaxime are generally dose‑related and vary with patient factors.

Common Side Effects: - Diarrhea: mild to moderate watery stools. - Nausea: occasional upset stomach. - Rash: transient erythematous skin eruptions. - Injection site pain: discomfort at the infusion site. - Elevated liver enzymes: transient increase in hepatic transaminases. - Headache: mild, self‑limiting.

Serious or Rare Side Effects: - Anaphylaxis: acute, potentially life‑threatening hypersensitivity. - Stevens‑Johnson syndrome: severe mucocutaneous reaction. - Clostridioides difficile‑associated colitis: severe diarrhea due to bacterial overgrowth. - Neutropenia: marked reduction in neutrophil count. - Renal impairment: acute kidney injury, especially with high doses. - Hepatotoxicity: significant liver enzyme elevation or jaundice.

When using Oximezin, clinicians should assess patient history and monitor relevant clinical parameters.

- Renal function: adjust dose in patients with impaired clearance. - Hepatic function: monitor liver enzymes during prolonged therapy. - Allergy history: avoid in patients with known cephalosporin or penicillin hypersensitivity. - Concomitant nephrotoxic drugs: use caution to reduce risk of kidney injury. - Pregnancy and lactation: weigh benefits against potential risks; use only if clearly indicated. - Store at below 25°C: keep in the original container, protect from moisture and light.

Cefotaxime may interact with several co‑administered medicines, altering efficacy or safety.

Major Interactions (Avoid): - Aminoglycosides: increased risk of nephrotoxicity when given together. - Loop diuretics: heightened potential for ototoxicity. - Warfarin: may enhance anticoagulant effect, requiring INR monitoring.

Moderate Interactions (Monitor Closely): - Probenecid: reduces renal excretion of cefotaxime, increasing serum levels. - Oral contraceptives: possible reduction in contraceptive efficacy. - Antacids containing magnesium or aluminum: may impair absorption if given concurrently.